What is BiomX Financial Strength?
BiomX has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
BiomX did not have earnings to cover the interest expense.
As of today, BiomX's Altman Z-Score is 0.00.
Competitive Comparison of BiomX's Financial Strength
For the Biotechnology subindustry, BiomX's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BiomX's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BiomX's Financial Strength distribution charts can be found below:
* The bar in red indicates where BiomX's Financial Strength falls into.
BiomX Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
BiomX's Interest Expense for the
months ended in Sep. 2024 was $-0.01 Mil. Its Operating Income for the
months ended in Sep. 2024 was $-10.53 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $8.65 Mil.
BiomX's Interest Coverage for the quarter that ended in Sep. 2024 is
| BiomX did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
BiomX's Debt to Revenue Ratio for the quarter that ended in Sep. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
BiomX has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiomX Business Description
Traded in Other Exchanges
N/A
Address
22 Einstein Street, Floor 4, Ness Ziona, ISR, 7414003
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
Executives
| Orbimed Israel Biofund Gp Limited Partnership |
director, 10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
| Assaf Oron |
officer: Chief Business Officer |
C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Eddie Williams |
director |
260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| Michael E. Dambach |
director |
22 EINSTEIN STREET, FLOOR 4, NESS ZIONA L3 7414003 |
| Jason M. Marks |
director |
C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807 |
| Carl L Gordon |
10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Chidozie Ugwumba |
10 percent owner |
158 FILMORE STREET, DENVER CO 80206 |
| Thomas Layton Walton |
10 percent owner |
P.O. BOX 1860, BENTONVILLE AR 72712 |
| Paul J Sekhri |
director |
C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588 |
| Lynne Marie Sullivan |
director |
C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139 |
| Marina Wolfson |
officer: Principal Financial Officer |
C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Jonathan Eitan Solomon |
director, officer: Chief Executive Officer |
C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Alan Charles Moses |
director |
C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Russell Greig |
director |
C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM |
| Gbolahan Amusa |
director |
17 STATE STREET 21 FLOOR, NEW YORK NY 10004 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PHGE has been successfully added to your